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Abstract
Background
Despite effective antiretroviral treatment (ART), HIV-positive individuals are at increased
risk of serious non-AIDS conditions (cardiovascular, liver and renal disease, and cancers),
perhaps due in part to ongoing inflammation and/or coagulation. To estimate the potential
risk reduction in serious non-AIDS conditions or death from any cause that might be
achieved with treatments that reduce inflammation and/or coagulation, we examined asso-
ciations of interleukin-6 (IL-6), D-dimer, and high-sensitivity C-reactive protein (hsCRP) lev-
els with serious non-AIDS conditions or death in 3 large cohorts.
Methods
In HIV-positive adults on suppressive ART, associations of IL-6, D-dimer, and hsCRP levels
at study entry with serious non-AIDS conditions or death were studied using Cox regres-
sion. Hazard ratios (HR) adjusted for age, gender, study, and regression dilution bias (due
to within-person biomarker variability) were used to predict risk reductions in serious non-
AIDS conditions or death associated with lower “usual” levels of IL-6 and D-dimer.
Results
Over 4.9 years of mean follow-up, 260 of the 3766 participants experienced serious non-
AIDS conditions or death. IL-6, D-dimer and hsCRP were each individually associated with
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risk of serious non-AIDS conditions or death, HR = 1.45 (95% CI: 1.30 to 1.63), 1.28 (95%
CI: 1.14 to 1.44), and 1.17 (95% CI: 1.09 to 1.26) per 2x higher biomarker levels, respec-
tively. In joint models, IL-6 and D-dimer were independently associated with serious non-
AIDS conditions or death, with consistent results across the 3 cohorts and across serious
non-AIDS event types. The association of IL-6 and D-dimer with serious non-AIDS condi-
tions or death was graded and persisted throughout follow-up. For 25% lower “usual” IL-6
and D-dimer levels, the joint biomarker model estimates a 37% reduction (95% CI: 28 to
46%) in the risk of serious non-AIDS conditions or death if the relationship is causal.
Conclusions
Both IL-6 and D-dimer are independently associated with serious non-AIDS conditions or
death among HIV-positive adults with suppressed virus. This suggests that treatments that
reduce IL-6 and D-dimer levels might substantially decrease morbidity and mortality in
patients on suppressive ART. Clinical trials are needed to test this hypothesis.
Introduction
Among HIV-positive adults with high CD4 cell counts on effective antiretroviral therapy
(ART), serious non-AIDS conditions (SNA) are the primary cause of severe morbidity and
mortality [1–4]. Among HIV-positive adults, higher levels of interleukin-6 (IL-6), D-dimer,
and high-sensitivity C-reactive protein (hsCRP) are associated with an increased risk of cardio-
vascular disease (CVD) [5–7], cancer [8], and all-cause mortality [9–11]. While ART decreases
IL-6, D-dimer and hsCRP levels [10, 12], these biomarkers remain elevated relative to the gen-
eral population even when the plasma HIV RNA is suppressed [13]. Markers of inflammation
and coagulation have been widely studied in the general population, and related to higher risk
of CVD [14–22], cancer [23–25], kidney function decline [26] and all-cause mortality [27–29].
These data collectively suggest that chronic inflammation and/or hyper-coagulation contribute
to the pathogenesis of these serious non-AIDS events during otherwise effective ART.
Given the assumed, albeit unproven, role of these pathways in causing disease, both vascular
and non-vascular, there is intense interest in studying interventions that reduce inflammation
and/or coagulation [30, 31]. To date, no single biomarker has been formally validated as a sur-
rogate marker for non-AIDS morbidity. We developed a biomarker score (the “IL-6 & D-
dimer score”), which optimally combines markers of inflammation and coagulation to predict
the risk of serious non-AIDS conditions or death from any cause (SNA/death) among HIV-
infected adults on suppressive ART, and a biomarker model to estimate the effect of sustained
long-term reductions in IL-6 and D-dimer levels on the risk of SNA/death. The IL-6 & D-
dimer score could be a suitable biomarker endpoint for phase II trials aiming to compare treat-
ments side-by-side for their potential to reduce serious non-AIDS conditions, even if the treat-
ments have different mechanisms of action, or target inflammation and/or coagulation to
varying degrees.
Methods
Population
Our analysis includes 3766 HIV-positive participants on suppressive ART from the control
arms of three studies performed by the INSIGHT trials network: the Strategies for
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Management of Antiretroviral Therapy (SMART; 1748 participants) [32, 33], Evaluation of
Subcutaneous Proleukin1 in a Randomized International Trial (ESPRIT; 1446 participants)
and Subcutaneous Recombinant, Human Interleukin-2 in HIV-Infected Patients with Low
CD4+ Counts under Active Antiretroviral Therapy (SILCAAT; 572 participants) [34] trials.
All participants were using ART at study entry, had HIV RNA levels 500 copies/mL, had
been randomized to continuing suppressive ART, and provided consent to store blood for
future research. We restricted our analysis to participants who were treated and virally sup-
pressed, because early treatment and viral suppression is increasingly the norm, and because
effective ART also decreases levels of inflammation and coagulation [10, 12]. These three stud-
ies comprised all large HIV trials conducted by the INSIGHT network in the past 15 years that
enrolled ART-experienced participants.
The study was conducted in accordance with the declaration of Helsinki. The SMART,
ESPRIT and SILCAAT trials were approved by the Institutional Review Board at the University
of Minnesota and the institutional review boards or institutional ethics committees at each of
the participating clinical sites worldwide. The Institutional Review Board at the University of
Minnesota also approved plans for the analysis of stored specimens for consenting participants.
All participants provided written informed consent. Clinicaltrials.gov identifiers:
NCT00027352, NCT00004978 and NCT00013611.
Outcome measures
The primary outcome was SNA/death, a composite endpoint comprising cardiovascular dis-
ease (myocardial infarction, stroke, or death due to cardiovascular disease including sudden
death not attributed to other causes), end-stage renal disease, decompensated liver cirrhosis,
non-AIDS cancer (excluding non-fatal non-melanoma skin cancer), and death due to any
cause. In the SMART and ESPRIT trials, clinical events were assessed by an independent End-
point Review Committee (ERC), blinded to randomization assignment. Only outcomes
assessed as confirmed or probable were included. In the SILCAAT study, SNA events were
identified from serious adverse event reports. Non-fatal events were coded according to the
Medical Dictionary for Regulatory Activities (MedDRA1) version 12.0 [35], causes of death
according to the CoDe system [36].
Biomarkers
We focused on IL-6, hsCRP, and D-dimer for several reasons. First, in a panel of 6 plasma bio-
markers measured in the INSIGHT SMART study, these 3 biomarkers were strongly associated
with all-cause mortality, which motivated us to determine these markers also for the ESPRIT
and SILCAAT trials, using stored baseline plasma specimens.[6] Second, higher levels of IL-6,
hsCRP and D-dimer have been associated with increased risk of CVD, cancer, and all-cause
mortality among people living with HIV [5–11], as well as in the general population [14–25,
27–29]. Third, the biomarkers have high laboratory and biological reproducibility. [37]
Levels of IL-6, D-dimer and hsCRP at study entry were measured on plasma collected at
baseline for all patients who provided written consent, and stored at -70 degrees Celsius. For
the SMART study, the biomarkers were determined centrally at the Laboratory for Clinical
Biochemistry Research at the University of Vermont (Burlington), for the ESPRIT and SIL-
CAAT trials, by SAIC-Frederick (Frederick, MD). IL-6 was measured by ELISA assays by R&D
Systems, Minneapolis, MN, using the QuantiGlo1 Chemiluminescent ELISA (range 0.48–
1500 pg/mL) for SMART and the high-sensitivity Quantikine1HS ELISA (range 0.16–10 pg/
mL) for ESPRIT and SILCAAT samples. The QuantiGlo1 Chemiluminescent ELISA was cho-
sen for SMART because HIV-positive populations have higher levels of IL-6 than the general
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population, and this assay’s range is wider while still giving sufficient precision at the lower
limit. Our laboratories validated that the two R&D ELISA assays provided similar measure-
ments, using split samples. D-dimer was measured by ELISA on the Sta-R analyzer, Liatest
D-DI (Diagnostic Stago, Parsippany, NJ, USA) for the SMART study, and on a VIDAS instru-
ment (BioMerieux Inc., Durham, NC, USA) for ESPRIT and SILCAAT. HsCRP was measured
by ELISA by both laboratories, using a NBTMII nephelometer, N Antiserum to Human CRP
(Siemens Diagnostics) for the SMART study, and an R&D Systems ELISA assay for ESPRIT
and SILCAAT. The D-dimer and hsCRP assays, while different, compared very well on dupli-
cate samples.[6] Lower limits of detection for D-dimer and hsCRP were 0.01 and 0.16 μg/mL,
respectively, for SMART, and 0.045 and 0.078 μg/mL for ESPRIT and SILCAAT. All samples
were analyzed blinded to clinical information about the participants.
Statistical Methods
Associations of baseline biomarker levels with SNA/death. In order to describe associa-
tions of individual biomarkers with SNA/death, we computed Kaplan-Meier estimates of the
cumulative risk of SNA/death by quartiles of baseline biomarker levels, and estimated hazard
ratios (HRs) per 2x higher baseline biomarker levels in separate Cox proportional hazards
models. All biomarkers were analyzed on the log2 scale, because their distributions were
skewed on the original scale. All proportional hazards models were adjusted for age (categories
18–40, 41–50 and 51+ years), sex, and study (ESPRIT, SILCAAT, SMART), because these
covariates were independently associated with SNA/death in a joint biomarker model.
In order to investigate whether IL-6, D-dimer and hsCRP are independently associated with
the risk of SNA/death, we started with a model that contained all three biomarkers, as well as
age, sex, race, study indicator, baseline CD4 cell counts (in categories500, 500–800, 801
+ cells/μL), nadir CD4, and indicator variables for the use of protease inhibitors (PIs) and non-
nucleoside reverse transcriptase inhibitors (NNRTIs) at baseline, and stepwise eliminated
covariates that did not improve the AIC model fit [38]. The final model contained log2 IL-6,
log2 D-dimer, age, sex, and the study indicator, each with p-values0.05. Because in the gen-
eral population BMI is associated with the risk of CVD and death, we also tested for an associa-
tion between BMI and the risk of SNA/death by adding BMI to the final biomarker model. We
did not include BMI in the formal backwards variable selection procedure, because we were
missing BMI values for 52 participants.
The IL-6 & D-dimer score was determined as the log HR estimate for given IL-6 and D-
dimer levels using the final proportional hazards model, which included the two log2-trans-
formed biomarkers, age, sex and the study indicator. Therefore, the score is a linear combina-
tion of the log2 biomarkers, weighted by the estimated regression coefficients. We tested the
proportional hazards assumption using the product of the score with log-transformed time.
As sensitivity analyses, we estimated associations of IL-6, D-dimer, and the IL-6 & D-dimer
score with each of the components of SNA/death in proportional hazards models, again
adjusted for age, sex and study indicator. We compared the associations of the IL-6 & D-dimer
score with the risk of SNA/death across subgroups by age, sex, and study cohort by testing for
the interaction effects between score and subgroup indicator. In order to assess whether the
association between the IL-6 & D-dimer score and the risk of SNA/death might have been
driven by the presence of subclinical disease at baseline, we performed two analyses. First, we
estimated the associations with events during the first 3 years (censoring later follow-up) and
with later events (by excluding participants with events prior to year 3), and compared the
associations during the earlier versus later time periods by adding the time-updated indicator
function of years 4–10 to the proportional hazards model. Second, we compared the
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associations of the IL-6 & D-dimer score with the risk of SNA/death in participants who had
experienced non-fatal SNA events prior to enrollment to the associations between score and
risk in participants without prior SNA events, by testing for an interaction effect between the
prior event status and the score. The latter analysis was restricted to the SMART and ESPRIT
participants, because the history of prior non-AIDS events was not collected in the SILCAAT
study.
Correction for regression dilution to estimate the effect of reducing the “usual” bio-
marker levels. Associations between a person’s “usual” biomarker levels (within-person long-
term average levels) with the risk of SNA/death are stronger than those of single, baseline bio-
marker measurements, due to measurement error and random within-person fluctuations in
the biomarkers over time. To correct for this regression dilution, the reliability coefficients for
IL-6, D-dimer, and the IL-6 & D-dimer score were estimated using biomarker data collected at
baseline, 1 and 3 years for 235 participants on stable ART in the ESPRIT study [39, 40]. To esti-
mate the reliability coefficients, variance components were estimated using longitudinal mixed
models for the biomarkers and the score, adjusted for visit by treatment group, age and sex.
Similar adjustments for regression dilution bias have been carried out in previous studies of IL-
6 and D-dimer [14–16]. After adjusting for regression dilution bias, we estimated the potential
effect of a therapy-induced, sustained reduction of 0%-40% in IL-6 and/or D-dimer levels on
the risk of SNA/death using proportional hazards models, and summarized the estimates and
pointwise 95% confidence limits in contour plots.
We estimated the mean change in CD4 cell counts through follow-up using a longitudinal
mixed model with random intercept and fixed slope, adjusted for study indicator.
Analyses used SAS version 9.3 (SAS Institute, Cary, NC, USA) and R version 3.1 [41]. All
p-values are two-sided.
Results
Baseline characteristics
Baseline characteristics of the 3766 participants are summarized in Table 1. The median age
was 42 years and 21% were women. At study entry, median time since HIV diagnosis was
7.3 years and participants had used ART for a median of 4.9 years. All participants had plasma
HIV RNA levels 500 copies/mL. The median CD4 cell count was 500 cells/μL, median nadir
181 cells/μL. Twenty-seven percent had a prior AIDS diagnosis. Median (IQR) for IL-6, D-
dimer and hsCRP were 1.7 (1.1–2.7) pg/mL, 0.22 (0.15–0.35) μg/mL and 1.54 (0.67–3.60) μg/
mL, respectively (Table 1). The three biomarkers were pairwise correlated; Spearman’s correla-
tions between IL-6 and D-dimer, IL-6 and hsCRP, and D-dimer and hsCRP were 0.31, 0.46,
and 0.24, respectively (p<0.001 each).
Associations of baseline biomarker levels with SNA/death
Over a mean follow-up of 4.9 years, 260 participants experienced SNA/death (1.44 per 100 per-
son-years, 95% CI: 1.27 to 1.63). The first event was non-AIDS cancer for 97 participants
(37%), CVD for 82 (32%; 45 myocardial infarction, 19 stroke, 18 deaths due to CVD), decom-
pensated liver cirrhosis for 19 (7%), end-stage renal disease for 8 (3%), and death due to other
causes for 54 (21%) participants, including 14 deaths due to AIDS, and 8 due to violence, acci-
dent or suicide (Fig 1).
Fig 2, panels A-C, show Kaplan-Meier curves for time to SNA/death by quartiles of IL-6, D-
dimer and hsCRP at study entry. High baseline levels of IL-6 and D-dimer predict an elevated
risk of SNA/death over 5 years and longer; by year 5, the cumulative rate of SNA/death was
12.0% among participants in the highest quartile of IL-6, compared with 3.5% for participants
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in the lowest two quartiles (Fig 2A). The spread of the curves for D-dimer and hsCRP quartiles
was less dramatic but still significant (Fig 2B and 2C).
Estimated hazard ratios of SNA/death per 2x higher baseline levels of IL-6, D-dimer and
hsCRP are summarized in Fig 3A. In separate models, IL-6, D-dimer and hsCRP were each
individually associated with risk of SNA/death; the estimated hazard ratios per 2x higher bio-
marker levels were 1.45 (95% CI: 1.30 to 1.63) for IL-6, 1.28 (95% CI: 1.14 to 1.44) for D-dimer,
and 1.17 (95% CI: 1.09 to 1.26) for hsCRP; p<0.001 for each. All models were adjusted for age,
sex and study.
Mean CD4 cell count levels increased slightly through follow-up, by 14 cells/mm3 per year.
Development of the IL-6 & D-dimer biomarker score
We obtained a parsimonious joint biomarker model by applying backwards variable selection
to a proportional hazards regression model containing all three biomarkers along with several
other baseline factors. In the resulting joint biomarker model, both IL-6 and D-dimer were
independently associated with the risk of SNA/death (Fig 3A, joint model), and the log hazard
Table 1. Baseline characteristics a.
Median (IQR) or %
Characteristic Overall SMART ESPRIT SILCAAT
(n = 3766) (n = 1748) (n = 1446) (n = 572)
Age (years) 42 (37, 49) 45 40 41
Female (%) 21.2 25.8 17.4 16.6
Race/Ethnicity (%)
Black 16.4 24.9 8.6 10.1
White/Latino/Other 83.6 75.1 91.4 89.9
Location of Enrollment (%)
Asia 3.4 0.7 8.0 -
Australia, Europe, Israel 46.9 37.0 52.3 63.1
North America 37.4 49.0 23.5 36.9
South America 11.8 12.8 15.3 -
Africa 0.6 0.5 0.9 -
HIV-related factors
CD4 cell count (cells/mm3) 500 (365, 690) 654 452 205
Nadir CD4 (cells/mm3) 181 (70, 290) 230 176 57
Prior AIDS (%) 27.1 24.9 28.1 31.3
Years since HIV diagnosis 7.3 (4.0, 11.4) 8.4 6.0 6.3
Duration of ART use (years) 4.9 (2.5, 8,0) 6.0 4.2 3.9
Current use of a PI (%) 47.8 42.1 47.9 64.9
Current use of a NNRTI (%) 50.8 52.0 51.7 44.8
BMI (kg/m2) 24.1 (22.0, 26.6) 24.7 23.7 23.7
Biomarkers
IL-6 (pg/mL) 1.7 (1.1, 2.7) 1.6 1.9 1.7
D-dimer (μg/mL) 0.22 (0.15, 0.35) 0.18 0.26 0.25
hsCRP (μg/mL) 1.54 (0.67, 3.60) 1.72 1.42 1.34
Abbreviations: ART = antiretroviral therapy, hsCRP = high-sensitivity C-reactive protein, IL-6 = Interleukin-6, IQR = interquartile range, NNRTI = non-
nucleoside reverse transcriptase inhibitor, PI = protease inhibitor.
a All 3766 participants were using suppressive ART at baseline (HIV RNA  500 cp/mL), and were randomized to continue their ART regimen.
doi:10.1371/journal.pone.0155100.t001
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ratio for SNA/death per log2 IL-6 and log2 D-dimer units higher is estimated by the
IL6&D dimer score : 0:33 log2 IL6þ 0:16 log2D dimer:
Higher levels of the IL-6 & D-dimer score were associated with increased risk of SNA/death
(Figs 2D and 4) and each of its components (Fig 4). In particular, 2x higher levels of both IL-6
and D-dimer correspond to 1 unit higher for each of the two log2 biomarker components of
the score, an IL-6 & D-dimer score of 0.49, and an estimated hazard ratio of 1.64 (95% CI: 1.43
to 1.89; p<0.001) for SNA/death.
In the joint biomarker model, the estimated risk of SNA/death was higher for older partici-
pants (HR = 2.0 for ages 41–50 versus 18–40 years, 3.3 for older than 50 years versus 18–40
years, both p<0.001), men compared with women (HR = 1.62, p = 0.01), and for participants
in the SILCAAT study, which enrolled subjects with lower CD4 T cell counts (Table 1). The
associations of the IL-6 & D-dimer score with the risk of SNA/death, however, were homoge-
neous across age, sex, or study (p>0.99, 0.94, and 0.70, respectively, for the interactions
between the score and the factors). Baseline hsCRP, CD4, CD4 nadir, and use of PIs or
NNRTIs at baseline did not contribute independently to the risk and were excluded by the vari-
able selection procedure. Similarly, BMI was not independently associated with the risk of
SNA/death in the joint biomarker model (p = 0.08).
Associations of the IL-6 & D-dimer score with the risk of SNA/death remained stable over
time (p = 0.45 for a test of proportional hazards using log time). During the first 3 years, 2x
higher baseline levels of both IL-6 and D-dimer were associated with a hazard ratio of 1.65
(95% CI: 1.37 to 2.00; p<0.001), while the hazard ratio was 1.61 (95% CI: 1.31 to 1.98;
p<0.001) after the first 3 years (p = 0.69 for a difference in hazard ratios by time period). Asso-
ciations were also consistent across the SMART, ESPRIT and SILCAAT studies (p = 0.86 for
interaction between the IL-6 & D-dimer score and study indicator), across age groups
(p = 0.95), and for men compared with women (p = 0.89).
Fig 1. Composition of the serious non-AIDS disease or death (SNA/death) endpoint.Only the first event per participant is counted.
doi:10.1371/journal.pone.0155100.g001
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Fig 2. Kaplan-Meier estimates of the cumulative proportion of participants who experienced serious non-AIDS disease or
death (SNA/death), by quartiles of IL-6 (A), D-dimer (B), hsCRP (C), and the IL-6 & D-dimer score (D). Biomarkers were measured
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Non-fatal non-AIDS events prior to study entry were reported in the SMART and ESPRIT
studies. When excluding the 146 (4.6%) participants who had a prior myocardial infarction
(35), stroke (28), non-AIDS cancer (42), liver cirrhosis or hepatic steatosis (42), or end-stage
kidney disease (5), the hazard ratio for SNA/death among SMART and ESPRIT participants
changed from 1.62 to 1.57 (95% CI: 1.31 to 1.87, p<0.001) per 2x higher baseline levels of IL-6
and D-dimer; associations between the IL-6 and D-dimer score and the risk of SNA events
were similar for those with and without a history of prior SNA (p = 0.48 for the interaction).
Predicting the effect of reducing “usual” levels of IL-6 and/or D-dimer through ther-
apy. Estimated reliability coefficients were 0.39 (95% CI: 0.28 to 0.50) for IL-6, 0.53 (95% CI:
0.44 to 0.62) for D-dimer, and 0.43 (95% CI: 0.33 to 0.54) for the IL-6 & D-dimer score. Associ-
ations of “usual” (within-person long-term average) biomarker levels with the risk of SNA/
death are summarized in Fig 3B; in the joint biomarker model, the estimated hazard ratio per 2
times higher “usual” biomarker levels was 2.16 (95% CI: 1.64 to 2.84) for IL-6, 1.45 (95% CI:
1.09 to 1.93) for D-dimer, and 3.16 (95% CI: 2.28 to 4.37) for both. These hazard ratios were
estimated in proportional hazards models, adjusted for regression dilution, and for age, sex
and study.
Based on the joint biomarker model, after adjustment for regression dilution, we estimate
that a sustained, long-term reduction in levels of IL-6 and D-dimer by 25% would result in a
37% reduction in the risk of SNA/death (95% CI: 28% to 46%) (Fig 5). The contour plot in Fig
5A shows the estimated reduction in the risk of SNA/death for combinations of different
amounts (0%-40%) of sustained reductions in the “usual” IL-6 and/or D-dimer levels. A similar
risk reduction by 37% would also be predicted for a sustained reduction in IL-6 by 30% and D-
dimer by 12%, for example, or for a reduction in IL-6 by 20% and D-dimer by 33%. Limits of
95% confidence intervals are provided in Fig 5B and 5C.
Discussion
Clinical endpoint trials are needed to establish whether lowering levels of inflammation and/or
coagulation among HIV-positive individuals will decrease the risk of serious non-AIDS condi-
tions, the leading cause of severe morbidity and mortality in virally well-controlled HIV infec-
tion. [1–4] We have developed a novel IL-6 & D-dimer biomarker score, which could be used
as a primary biomarker outcome in phase II trials aiming to compare side-by-side drugs with
different mechanisms of action (decrease of inflammation and/or coagulation), by evaluating
treatments with respect to their model-predicted potential to reduce SNA/death.
We have shown that a single measurement of IL-6, D-dimer or hsCRP at baseline predicted
the risk of SNA/death over 5 years and longer in a large cohort of HIV-positive individuals on
suppressive ART regimens with moderate or high CD4 cell counts. Higher baseline levels of
IL-6, D-dimer and hsCRP were associated with increased risk of SNA/death when considered
separately, and IL-6 and D-dimer were independently associated with the risk in a joint bio-
marker model.
We combined CVD, cancer, serious renal and hepatic disease, and all-cause mortality into
the composite outcome of SNA/death, because each of these conditions had been linked indi-
vidually to high levels of inflammation and/or coagulation in the general population as well as
among HIV-positive individuals. Markers of inflammation and coagulation have been most
widely studied for their association with CVD [6, 7, 14–22] and all-cause mortality [10, 11, 27–
29]. Currently, a clinical trial is ongoing to test whether reduction in inflammation through
at study entry. At 5 years, the risk of SNA/death was 12.0% for participants in the highest quartile of IL-6, compared with 3.5% for
participants in the two lowest quartiles. Abbreviations: IL-6 = Interleukin-6; hsCRP = high-sensitivity C-reactive protein.
doi:10.1371/journal.pone.0155100.g002
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low-dose methotrexate reduces CVD or death in the general population [42], as well as a trial
to test whether statin therapy prevents CVD among HIV-infected individuals using ART [43].
However, systemic inflammation and activation of coagulation appear to have broader effects
beyond CVD. Elevated levels of IL-6, hsCRP and/or D-dimer were predictive of cancer, in par-
ticular death due to cancer [16, 23, 24, 44]; high D-dimer levels were linked to cancer mortality
more strongly than to CVD [28]. Higher levels of inflammation and coagulation are also pre-
dictive of kidney function decline [26], and liver disease has been linked to increased coagula-
tion [45]. In our cohort, associations of elevated IL-6 & D-dimer scores with the risk of cancer,
kidney and liver disease, and all-cause mortality individually were at least as strong as associa-
tions with CVD. Associations of the IL-6 & D-dimer score with the risk of SNA/death were
also consistent across studies (SMART, ESPRIT, and SILCAAT), across age groups, similar for
men and women, and across baseline ART regimens.
Our biomarker models suggest that lowering levels of inflammation and/or coagulation
might substantially decrease non-AIDS morbidity and mortality among HIV-positive patients
on suppressive ART regimens, if inflammation and coagulation are on the causal pathway.
Suitable agents to test this hypothesis in a clinical trial could target inflammation or coagula-
tion to varying degrees, but would have to be safe for long-term use in combination with ART.
Phase II trials would be needed to evaluate safety along with the potential to decrease inflam-
mation or coagulation. The IL-6 & D-dimer score combines markers of inflammation and
coagulation optimally to estimate the risk of SNA/death, and such could be used as biomarker
outcome in pilot trials to compare several candidate agents.
Within the limitations of a prospective cohort study, we performed analyses to address the
possibility that the associations of elevated baseline levels of IL-6 and D-dimer with the risk of
SNA/death might have been due to subclinical disease which increased the biomarker levels as
well as the subsequent risk of clinical disease. In our cohort, the strength of the associations
between baseline biomarkers and risk of SNA/death remained stable through follow-up in, and
associations of the IL-6 & D-dimer score with SNA/death were similar for participants with
and without a prior history of non-fatal SNA events. These findings suggest that the associa-
tions are not explained by subclinical disease.
The main strength of our study was the large cohort of well-characterized participants, cen-
trally determined biomarkers, the standardized definition of SNA events across the cohort, and
the rigorous adjudication of the events in the SMART and ESPRIT cohorts by an independent
ERC. The study has several limitations. First, we considered only three biomarkers; other markers
might provide even stronger risk predictions. Second, the biomarkers were determined in two
different central laboratories. Analyses of 20 repeated samples across the laboratories showed
similar values, however [6]; also, all models included the study indicator, and thereby adjusted
for potential differences between the two laboratories. Third, biomarker levels are highly variable
within subjects, both due to assay variability as well as due to natural fluctuations. While we
adjusted our estimates for the resulting regression dilution bias, the statistical uncertainty inher-
ent in the biomarker measures resulted in large confidence intervals for the hazard ratios. Lastly,
the SMART, ESPRIT and SILCAAT trials were conducted in 1997–2008, and it is possible that
results would be slightly different in a population receiving more current ART regimens.
Fig 3. Hazard ratios (HRs) for serious non-AIDS conditions or death (SNA/death) per 2x higher levels of IL-6, D-dimer, and
hsCRP. Panel A shows HRs for differences in baseline biomarker levels (a one-time measurement), estimated using proportional
hazards models for each biomarker separately, and in a joint biomarker model containing both IL-6 and D-dimer. Panel B shows
HRs for differences in “usual” (the within-subject long-term average) biomarker levels, estimated in separate and joint biomarker
models after adjustment for regression dilution bias. All models were adjusted for age, sex, and study indicator (SMART, ESPRIT,
SILCAAT). Abbreviations: IL-6 = Interleukin-6; hsCRP = high-sensitivity C-reactive protein.
doi:10.1371/journal.pone.0155100.g003
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In summary, both IL-6 and D-dimer independently predict the risk of serious non-AIDS
conditions or death among HIV-positive patients with suppressed virus and moderate to high
Fig 4. Estimated hazard ratios (HR) for the composite endpoint of serious non-AIDS or death (SNA/death) and its components.
Hazard ratios are estimated per 2x higher level of IL-6 and D-dimer, with 95% confidence intervals. Two times higher biomarker levels
corresponds to 1 unit higher on the log2 biomarker scale, and 0.49 units higher for the IL-6 & D-dimer score. Hazard ratios were
estimated in proportional hazards models adjusted for age, sex and study. Footnotes:Of the 144 deaths, 37 were due to non-AIDS
cancer, 33 CVD, 11 non-cancer hepatic disease, 1 renal failure, 15 AIDS-related, 9 due to violence, accident or suicide, 38 due to other
or unknown causes. Abbreviations: CI = confidence interval; CVD = cardiovascular disease (myocardial infarction, stroke, and death
due to CVD); HR = hazard ratio.
doi:10.1371/journal.pone.0155100.g004
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CD4 cell counts. Treatments to decrease IL-6 and D-dimer might substantially reduce morbid-
ity and mortality in HIV-positive patients on suppressive ART, since non-AIDS conditions
dominate morbidity in this population. Clinical trials are needed to test this hypothesis. The
Fig 5. Estimated risk reduction. Panel A: Contour plot of the estimated reduction in the risk of serious non-AIDS conditions or
death (SNA/death) when “usual” (within-person long-term average) levels of IL-6 and/or D-dimer are decreased by 0–40%,
possibly through an intervention. Solid lines show predicted risk reductions of 5%, 10%, etc. Panels B and C show the lower and
upper 95% confidence limits, respectively. For a 25% reduction in IL-6 and D-dimer, the risk of SNA/death is predicted to decline
by 37% (95%CI: 28 to 46%). Footnotes: The reduction in the risk was estimated using Cox proportional hazards models,
adjusted for regression dilution bias, and for age, sex, and study. Reliability coefficients for the regression dilution adjustment
were estimated using longitudinal mixed models for biomarker data collected at baseline, years 1 and 3 for 235 participants on
stable ART in the ESPRIT study. Abbreviations: CI = confidence interval; IL-6 = Interleukin-6.
doi:10.1371/journal.pone.0155100.g005
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IL-6 & D-dimer score could be a suitable biomarker outcome in phase II trials to compare
drugs with different mechanisms of action (targeting inflammation, coagulation, or both) for
their estimated, model-predicted potential to reduce non-AIDS morbidity and mortality.
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